Average Co-Inventor Count = 7.27
ph-index = 8
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Abb Vie Deutschland Gmbh & Co. Kg (20 from 150 patents)
2. Abbott Gmbh & Co Kg (20 from 139 patents)
3. Abbvie Inc. (15 from 822 patents)
4. Abbott Laboratories Corporation (9 from 4,177 patents)
5. Abbvie Deutschland Gmbh and Co Kg (17 patents)
49 patents:
1. 10556907 - Fused heterocyclic compounds as S1P modulators
2. 10556914 - Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use
3. 10155770 - Substituted pyrazolopyrimidines and method of use
4. 10100048 - Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
5. 9879033 - Modulators of 5-HT receptors and methods of use thereof
6. 9856234 - Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
7. 9828381 - Substituted pyrazolopyrimidines and method of use
8. 9790203 - Inhibitor compounds of phosphodiesterase type 10A
9. 9657034 - Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors
10. 9540370 - Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
11. 9273068 - Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A
12. 9266855 - Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
13. 9238619 - Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
14. 9187483 - Modulators of 5-HT receptors and methods of use thereof
15. 9163007 - 5-substituted indazoles as kinase inhibitors